Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer

被引：0
|
作者：
Jang, T. W. [1 ]
Kim, T. [2 ]
机构：
[1] Kosin Univ Gospel Hosp, Busan, South Korea
[2] Armed Forces Goyang Hosp, Goyang, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Afatinib; osimertinib; real-world effectiveness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-27
引用
收藏
页码：S651 / S651
页数：1
相关论文
共 50 条
  • [1] Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study
    Kim, Taeyun
    Jang, Tae Won
    Choi, Chang Min
    Kim, Mi-Hyun
    Lee, Sung Yong
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Chan Kwon
    Lee, Sang Hoon
    Jang, Seung Hun
    Yoon, Seong Hoon
    Oh, Hyung-Joo
    CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1152 - 1170
  • [2] Afatinib in EGFR mutation positive advanced non-small cell lung cancer
    Davies, R. S.
    Brewster, A. E.
    Button, M. R.
    Lester, J. F.
    LUNG CANCER, 2016, 91 : S22 - S22
  • [3] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Igawa, Satoshi
    Ono, Taihei
    Kasajima, Masashi
    Kusuhara, Seiichiro
    Otani, Sakiko
    Fukui, Tomoya
    Yokoba, Masanori
    Kubota, Masaru
    Katagiri, Masato
    Mitsufuji, Hisashi
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1906 - 1914
  • [4] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Satoshi Igawa
    Taihei Ono
    Masashi Kasajima
    Seiichiro Kusuhara
    Sakiko Otani
    Tomoya Fukui
    Masanori Yokoba
    Masaru Kubota
    Masato Katagiri
    Hisashi Mitsufuji
    Jiichiro Sasaki
    Katsuhiko Naoki
    Investigational New Drugs, 2020, 38 : 1906 - 1914
  • [5] Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations
    Chen, Chi-Han
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Hsu, Ping-Chih
    Wu, Chiao-En
    ANTICANCER RESEARCH, 2022, 42 (04) : 2145 - 2157
  • [6] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [7] Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients
    Uy, Natalie F.
    Tratt, Micah
    Eaton, Keith D.
    Santana-Davila, Rafael
    Baik, Christina S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A.
    Jimeno, A.
    DRUGS OF TODAY, 2013, 49 (09) : 523 - 535
  • [9] Sequential afatinib and osimertinib in patients withEGFRmutation-positive non-small-cell lung cancer: final analysis of the GioTag study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Marten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2020, 16 (34) : 2799 - 2808
  • [10] Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
    Noorwati SUTANDYO
    Arif HANAFI
    Mulawarman JAYUSMAN
    中国肺癌杂志, 2019, (09) : 562 - 567
12345